Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET
31 Maio 2023 - 9:00AM
Vaxart, Inc. (NASDAQ: VXRT) today announced it is launching an
investor communication program that will give investors the ability
to ask questions of Company management. The first event will be a
fireside chat with Vaxart executives on Thursday, June 15 at 11
a.m. ET.
“Investor support is the lifeblood of a
developing biotechnology company, and we are excited to further the
ongoing dialogue with our shareholders,” said Andrei Floroiu,
Vaxart’s Chief Executive Officer. “Our leadership team communicates
with investors through several channels, and this program provides
us with an additional means to keep investors informed about the
Company. We look forward to sharing our progress as we advance our
oral vaccine platform.”
The new investor communication program is
available in the Investor Resources section of Vaxart’s Investor
Relations webpage. Individuals will have the opportunity to submit
questions in advance of each event.
About Vaxart Vaxart is a
clinical-stage biotechnology company developing a range of oral
recombinant vaccines based on its proprietary delivery platform.
Vaxart vaccines are designed to be administered using pills that
can be stored and shipped without refrigeration and eliminate the
risk of needle-stick injury. Vaxart believes that its proprietary
pill vaccine delivery platform is suitable to deliver recombinant
vaccines, positioning the company to develop oral versions of
currently marketed vaccines and to design recombinant vaccines for
new indications. Vaxart’s development programs currently include
pill vaccines designed to protect against norovirus, coronavirus,
seasonal influenza, and respiratory syncytial virus (RSV), as well
as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s
first immune-oncology indication. Vaxart has filed broad domestic
and international patent applications covering its proprietary
technology and creations for oral vaccination using adenovirus and
TLR3 agonists.
Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements, other than statements of historical facts, included in
this press release regarding Vaxart's strategy, prospects, plans
and objectives, results from preclinical and clinical trials,
commercialization agreements and licenses, and beliefs and
expectations of management are forward-looking statements. These
forward-looking statements may be accompanied by such words as
"should," "believe," "could," "potential," "will," "expected,"
"anticipate," "plan," and other words and terms of similar meaning.
Examples of such statements include, but are not limited to,
statements relating to Vaxart's ability to develop and
commercialize its product candidates, including its vaccine booster
products; Vaxart's expectations regarding clinical results and
trial data; and Vaxart's expectations with respect to the
effectiveness of its product candidates. Vaxart may not actually
achieve the plans, carry out the intentions, or meet the
expectations or projections disclosed in the forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations, and
projections disclosed in the forward-looking statements. Various
important factors could cause actual results or events to differ
materially from the forward-looking statements that Vaxart
makes.
Please also refer to the risks described in the
"Risk Factors" sections of Vaxart's Quarterly and Annual Reports
filed with the SEC. Vaxart does not assume any obligation to update
any forward-looking statements, except as required by law.
Contacts
Vaxart Media
Relations: |
Investor
Relations: |
Mark Herr |
Andrew Blazier |
Vaxart, Inc. |
Finn Partners |
mherr@vaxart.com |
IR@Vaxart.com |
(203) 517-8957 |
(646)
871-8486 |
Vaxart (NASDAQ:VXRT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Vaxart (NASDAQ:VXRT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024